Calyxt, Inc. – NASDAQ:CLXT

Financial Health
0
1
2
3
4
5
6
7
8
9

Calyxt stock price monthly change

+19.84%
month

Calyxt stock price quarterly change

+517.40%
quarter

Calyxt stock price yearly change

+8309.48%
year

Calyxt key metrics

Market Cap
31.33M
Enterprise value
24.65M
P/E
-0.88
EV/Sales
157.03
EV/EBITDA
-1.61
Price/Sales
92.59
Price/Book
2.00
PEG ratio
N/A
EPS
-3.33
Revenue
756K
EBITDA
-52.88M
Income
-53.42M
Revenue Q/Q
1030.95%
Revenue Y/Y
-63.26%
Profit margin
-10758.6%
Oper. margin
-14248.41%
Gross margin
100%
EBIT margin
-14248.41%
EBITDA margin
-6995.24%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Calyxt stock price history

Calyxt stock forecast

Calyxt financial statements

Calyxt, Inc. (NASDAQ:CLXT): Profit margin
Dec 2022 42K -1.98M -4721.43%
Mar 2023 42K -6.32M -15059.52%
Jun 2023 197K -18.69M -9487.31%
Sep 2023 475K -26.42M -5564%
Calyxt, Inc. (NASDAQ:CLXT): Debt to assets
Dec 2022 22421000 15.18M 67.74%
Mar 2023 20285000 17.61M 86.85%
Jun 2023 814268000 193.08M 23.71%
Sep 2023 796235000 203.74M 25.59%
Calyxt, Inc. (NASDAQ:CLXT): Cash Flow
Jun 2022 -4.87M -744K -353K
Sep 2022 -4.32M -220K -164K
Dec 2022 -3.76M -11K 95K
Mar 2023 -2.37M 0 903K

Calyxt alternative data

Calyxt, Inc. (NASDAQ:CLXT): Employee count
Aug 2023 48
Sep 2023 48
Oct 2023 48
Nov 2023 48
Dec 2023 48
Jan 2024 48
Feb 2024 48
Mar 2024 48
Apr 2024 48
May 2024 48
Jun 2024 48
Jul 2024 48

Calyxt other data

28.26% +1.93%
of CLXT is owned by hedge funds
10.59M +775.66K
shares is hold by hedge funds

Calyxt, Inc. (NASDAQ:CLXT): Insider trades (number of shares)
Period Buy Sel
Jun 2023 1000 0
Dec 2023 517107 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
RIGGS RORY B director, 10 percent owner, off..
Class A Common Stock 517,107 $10.58 $5,470,992
Purchase
RIGGS RORY B director, 10 percent owner, off..
Class A Common Stock 1,000 $31.5 $31,500
Sale
RIBEILL YVES J director
Common Stock 30,000 $0.24 $7,170
Sale
RIBEILL YVES J director
Common Stock 20,000 $1.06 $21,240
Purchase
CARR MICHAEL A. director, officer: President an..
Common Stock 10,000 $3.98 $39,780
Purchase
KOSCHAK WILLIAM officer: Chief Fi.. Common Stock 20,000 $3.21 $64,120
Purchase
NEUGENT CHRISTOPHER J director
Common Stock 15,000 $3.95 $59,295
Sale
VOYTAS DANIEL F officer: Chief Science Officer
Common Stock 2,513 $4.13 $10,389
Sale
BLOME JAMES officer: Chief Executive Officer
Common Stock 4,140 $4.17 $17,280
Sale
VOYTAS DANIEL F officer: Chief Science Officer
Common Stock 5,026 $4.75 $23,874
Thursday, 9 March 2023
headlinesoftoday.com
Wednesday, 18 January 2023
PennyStocks
Tuesday, 17 January 2023
PennyStocks
InvestorPlace
Sunday, 6 November 2022
Seeking Alpha
Thursday, 3 November 2022
Zacks Investment Research
Sunday, 7 August 2022
Seeking Alpha
Thursday, 28 July 2022
PRNewsWire
Thursday, 21 July 2022
PRNewsWire
Sunday, 8 May 2022
Seeking Alpha
Thursday, 21 April 2022
PRNewsWire
Friday, 1 April 2022
Seeking Alpha
Thursday, 3 March 2022
Seeking Alpha
Zacks Investment Research
Thursday, 24 February 2022
PRNewsWire
Friday, 31 December 2021
InvestorPlace
Tuesday, 23 November 2021
PRNewsWire
Sunday, 7 November 2021
Seeking Alpha
Tuesday, 2 November 2021
PennyStocks
Thursday, 28 October 2021
Zacks Investment Research
Tuesday, 5 October 2021
PRNewsWire
Tuesday, 28 September 2021
Benzinga
PRNewsWire
  • When is Calyxt's next earnings date?

    Unfortunately, Calyxt's (CLXT) next earnings date is currently unknown.

  • Does Calyxt pay dividends?

    No, Calyxt does not pay dividends.

  • How much money does Calyxt make?

    Calyxt has a market capitalization of 31.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.4% to 157K US dollars.

  • What is Calyxt's stock symbol?

    Calyxt, Inc. is traded on the NASDAQ under the ticker symbol "CLXT".

  • What is Calyxt's primary industry?

    Company operates in the Consumer Defensive sector and Packaged Foods industry.

  • How do i buy shares of Calyxt?

    Shares of Calyxt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Calyxt's key executives?

    Calyxt's management team includes the following people:

    • Mr. William F. Koschak Chief Financial Officer(age: 56, pay: $481,460)
    • Dr. Travis J. Frey Ph.D. Chief Technology Officer(age: 47, pay: $426,760)
  • How many employees does Calyxt have?

    As Jul 2024, Calyxt employs 48 workers.

  • When Calyxt went public?

    Calyxt, Inc. is publicly traded company for more then 8 years since IPO on 20 Jul 2017.

  • What is Calyxt's official website?

    The official website for Calyxt is calyxt.com.

  • Where are Calyxt's headquarters?

    Calyxt is headquartered at 2800 Mount Ridge Road, Roseville, MN.

  • How can i contact Calyxt?

    Calyxt's mailing address is 2800 Mount Ridge Road, Roseville, MN and company can be reached via phone at +65 16832807.

Calyxt company profile:

Calyxt, Inc.

calyxt.com
Exchange:

NASDAQ

Full time employees:

48

Industry:

Packaged Foods

Sector:

Consumer Defensive

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.

2800 Mount Ridge Road
Roseville, MN 55113-1127

CIK: 0001705843
ISIN: US13173L1070
CUSIP: 13173L107